Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review (Q35805765)

10 August 2017

1 reference

title

Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review (English)

1 reference

10 August 2017

author

Steen Bendix Haugaard

object named as

Steen B Haugaard

2

0 references

Ove Andersen

object named as

Ove Andersen

5

0 references

Jens Ole Nielsen

4

object named as

Jens Ole Nielsen

1 reference

10 August 2017

Birgitte R Hansen

1

1 reference

10 August 2017

Johan Iversen

3

1 reference

10 August 2017

publication date

1 January 2004

1 reference

Scandinavian Journal of Infectious Diseases

10 August 2017

published in

1 reference

10 August 2017

volume

36

1 reference

10 August 2017

issue

4

1 reference

10 August 2017

page(s)

244-253

1 reference

Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

An objective case definition of lipodystrophy in HIV-infected adults: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Cardiovascular Risk Factors in HIV-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Changes in metabolic parameters and body shape after replacement of protease inhibitor With efavirenz in virologically controlled HIV-1-positive persons: single-arm observational cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Changes in AIDS incidence for men who have sex with men, United States 1990-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Switch to efavirenz in a protease inhibitor-containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Studies of body composition and fat distribution in HIV-infected and control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

Reversal of hyperlipidemia and lipodystrophy in patients switching therapy to nelfinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410019381

10.1080/00365540410019381

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference